Advertisement
Research Article

Acceptability of Carraguard Vaginal Microbicide Gel among HIV-Infected Women in Chiang Rai, Thailand

  • Sara J. Whitehead mail,

    svw7@th.cdc.gov

    Affiliation: Thailand Ministry of Public Health–U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand

    X
  • Catherine McLean,

    Affiliation: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Supaporn Chaikummao,

    Affiliation: Thailand Ministry of Public Health–U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand

    X
  • Sarah Braunstein,

    Affiliation: Population Council, New York, New York, United States of America

    X
  • Wat Utaivoravit,

    Affiliation: Chiang Rai Hospital, Chiang Rai, Thailand

    X
  • Janneke H. van de Wijgert,

    Affiliations: Population Council, New York, New York, United States of America, Academic Medical Center of the University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands

    X
  • Philip A. Mock,

    Affiliation: Thailand Ministry of Public Health–U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand

    X
  • Taweesap Siraprapasiri,

    Affiliation: Thailand Ministry of Public Health–U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand

    X
  • Barbara A. Friedland,

    Affiliation: Population Council, New York, New York, United States of America

    X
  • Peter H. Kilmarx,

    Affiliation: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Lauri E. Markowitz

    Affiliation: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Published: September 07, 2011
  • DOI: 10.1371/journal.pone.0014831

About the Authors

Sara J. Whitehead, Supaporn Chaikummao, Philip A. Mock, Taweesap Siraprapasiri
Thailand Ministry of Public Health–U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand
Catherine McLean, Peter H. Kilmarx, Lauri E. Markowitz
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
Sarah Braunstein, Janneke H. van de Wijgert, Barbara A. Friedland
Population Council, New York, New York, United States of America
Wat Utaivoravit
Chiang Rai Hospital, Chiang Rai, Thailand
Janneke H. van de Wijgert
Academic Medical Center of the University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands

Corresponding Author

Email: svw7@th.cdc.gov

Competing Interests

None of the authors have a commercial association with Carraguard or other conflicts of interest. Carraguard® is being developed by the Population Council, which is a not-for-profit nongovernmental organization, under a U.S. Food and Drug Administration Investigational New Drug Application (IND 58,441).

Author Contributions

Conceived and designed the experiments: JvdW CAM BF PHK LEM. Performed the experiments: CAM SC. Analyzed the data: SJW PAM. Wrote the manuscript: SJW. Contributed to study monitoring and implementation: JvdW. Supervised field staff: SJW SC. Developed Standard Operating Procedures, monitored trial conduct, contributed to analysis of acceptability data: SB. Coordinated field site support and referral: WU. Coordinated field staff supervision and implementation: TS. Supported implementation of the study: BF. Supervised implementation of the study: PHK LEM.